Access to healthcare

Access to healthcare is a serious issue for many people around the world, and Shionogi is committed as part of its social responsibility as a pharmaceutical company to continuing the pursuit of this Company Policy through earnest initiatives to improve healthcare access.

With a view to improving access to healthcare, we issued the Shionogi Global Health Access Policy Statement, which sets out our commitment to fulfilling our corporate mission by working, not only through our own efforts but also with a wide range of partners, to contribute to better health for people around the world, especially in developing countries. Specifically, we are progressing with the initiatives outlined below.

Shionogi’s initiatives for access to healthcare have received external recognition. With specific reference to its AMR initiatives, Shionogi was the only Japanese pharmaceutical company to qualify for inclusion in the Antimicrobial Resistance Benchmark 2018 survey, and was also recognized in the survey as having the highest annual ratio of R&D investment for anti-infectives of any of the companies surveyed (based on investment as a proportion of net sales).

Specifically, we are progressing with the initiatives outlined below.